Clinical Case Reviews of Management of Complex Spinal Degeneration, Nerve Compression, Surgery, and Supportive Cell Therapy

From a clinical perspective, the medical team considers this patient’s condition to be a complex multilevel spinal disorder rather than a single-disc problem or isolated source of back pain. His medical history suggests a combination of previous spinal fusion, degenerative disc and facet-joint disease, neural foraminal narrowing, nerve-root compression, radiating pain, bilateral foot drop, and prolonged dependence on opioid pain medication.

These findings should be assessed not only from an anatomical perspective, but also according to their impact on the patient’s neurological function, mobility, sleep, work, independence, and quality of life. Because the patient wishes to preserve mobility and potentially return to activities such as surfing, skiing, and snowboarding, the medical team recommends that treatment planning focus on both structural stability and long-term functional recovery.

Recommended Review of Imaging and Neurological Status The available imaging indicates multilevel degenerative disease involving the lumbar spine. The preoperative lumbar MRI demonstrated facet arthropathy, neural foraminal narrowing, an L3–L4 disc bulge, and a central L4–L5 disc protrusion with annular fissuring. At L4–L5, moderate bilateral neural foraminal narrowing was present with involvement of the L4 nerve roots. Postoperative changes were also noted at L5–S1, together with mild vertebral displacement at several levels.

Thoracic imaging demonstrated the previous T9–T11 fusion and mild multilevel degeneration, without significant thoracic cord compression at that time.

However, imaging findings should always be correlated with the patient’s neurological and functional condition. MRI and CT can identify structural pathology, but they do not fully demonstrate the severity of pain, walking limitations, sleep disturbance, weakness, or loss of independence.

For this reason, the medical team recommends ongoing assessment of:

• lower-extremity motor strength;

• foot-drop severity;

• gait and balance;

• sensory abnormalities;

• reflexes;

• walking and standing tolerance;

• radiating pain;

• bowel or bladder symptoms if present;

• functional limitations in daily life.

Figure 1: Composite lumbar imaging demonstrating the patient’s preoperative and postoperative findings.A: Preoperative lumbar MRI showing an L4–L5 disc protrusion with annular fissuring and associated neural foraminal narrowing.B: Postoperative imaging demonstrating spinal instrumentation and fusion.C: Postoperative lumbar CT showing the position of the spinal implants in relation to the surrounding bony structures.

When Surgical Management Should Take Priority In this case, the medical team recommends distinguishing clearly between biological symptoms such as inflammation and pain, and structural neurological problems caused by mechanical nerve compression or spinal instability.

When a patient develops progressive neurological deficits such as worsening radiculopathy, persistent nerve-root compression, spinal deformity, significant stenosis, or bilateral foot drop, supportive regenerative treatment alone is unlikely to be sufficient.

The decompression, instrumentation, and fusion performed at L3–L5 appear to have been appropriate for addressing the mechanical component of the condition.

This distinction is essential because cell therapy cannot:

• remove bone or tissue mechanically compressing a nerve;

• widen a severely narrowed neural foramen;

• correct spinal deformity;

• stabilise an unstable spinal segment;

• reposition screws or spinal implants.

Therefore, progressive neurological impairment should always prompt surgical or neurosurgical review before considering regenerative supportive care.

Recommended Postoperative Assessment

Before considering any postoperative regenerative treatment, the medical team recommends confirming that the patient has recovered sufficiently from surgery. Postoperative imaging demonstrated instrumentation and fusion at L3–L5 together with the previous L5–S1 fusion. Although no clear central spinal-canal stenosis was identified, assessment of some neural foramina was limited by metallic artefact.

The presence of a postoperative subcutaneous haematoma should also be considered before proceeding with elective injections or regenerative therapy.

The medical team therefore recommends reviewing:

• wound healing;

• signs of infection;

• postoperative haematoma or fluid collection;

• neurological status;

• updated MRI or CT when indicated;

• implant position and spinal stability;

• surgeon clearance;

• current anticoagulant or antiplatelet medication use;

• inflammatory and haematological blood results.

Regenerative treatment should only be considered when the postoperative condition is clinically stable.

Recommended Role of Cell Therapy

For this patient, the medical team positions cell therapy as an adjunctive biological support option rather than a substitute for surgery. Cell therapies are being investigated for their ability to release cytokines, growth factors, extracellular vesicles, and other signalling molecules that may influence inflammatory activity and the local tissue environment.

The proposed goals of cell therapy would be to:

• support inflammatory regulation;

• support tissues surrounding previously compressed or injured nerve roots;

• support comfort and mobility;

• complement physiotherapy and neurological rehabilitation;

• assist the biological environment during postoperative recovery.

It should be explained clearly that cell therapy cannot guarantee restoration of chronic nerve damage or bilateral foot drop and should not be described as rebuilding the entire spinal disc or reversing established spinal fusion.

Recommended Treatment Strategy

The medical team recommends a staged treatment approach rather than relying on a single modality.

Stage 1: Structural and Neurological Assessment Before treatment, review:

• updated lumbar MRI or CT;

• operative reports;

• current neurological examination;

• foot-drop severity;

• pain pattern;

• spinal stability;

• signs of persistent or recurrent nerve compression.

Stage 2: Targeted Supportive Regenerative Treatment If the patient is medically stable and there is no indication for further urgent structural intervention, a supportive regenerative programme may be considered. Potential components may include:

• targeted cell therapy administration around clinically relevant lumbar or thoracic regions;

• intravenous cell therapy when considered appropriate by the treating physician;

• PRP or other local biologic support for selected musculoskeletal structures;

• supportive intravenous therapy such as NAD+ or vitamin infusion when clinically appropriate.

The exact route, dose, and location should be determined according to imaging findings, examination, previous surgery, and procedural safety.

Stage 3: Rehabilitation The regenerative programme should be combined with structured rehabilitation. The medical team recommends particular attention to:

• gait retraining;

• ankle dorsiflexion strengthening;

• lower-limb strengthening;

• core stability;

• balance training;

• hip and pelvic control;

• flexibility and mobility;

• fall prevention;

• progressive cardiovascular conditioning.

Patients with bilateral foot drop may also require orthotic assessment, such as ankle-foot orthoses, depending on the degree of weakness.

Recommended Outcome Monitoring The effectiveness of supportive treatment should not be judged by subjective impressions alone.

The medical team recommends establishing baseline measurements before treatment and reassessing at 1, 3, 6, and 12 months.

Important outcome measures include:

• pain score;

• frequency of radiating pain;

• walking distance;

• standing tolerance;

• ankle dorsiflexion strength;

• lower-limb muscle strength;

• numbness and sensory changes;

• gait and balance;

• sleep quality;

• work and daily activity tolerance;

• opioid and other pain-medication use;

• physiotherapy progress;

• return to exercise or sport;

• quality-of-life measures;

• any adverse effects.

This is particularly important because there is currently insufficient structured follow-up information to determine how much improvement can specifically be attributed to cell therapy.

Recommendation Regarding Pain Medication Given the history of long-term opioid use, the medical team also recommends coordinated pain-management review.

Any reduction in opioid medication should be supervised rather than performed abruptly. The goal should be to improve function and reduce reliance on medication when clinically appropriate, while maintaining adequate pain control.

A multidisciplinary pain-management approach may include:

• physician-supervised medication adjustment;

• neuropathic pain medication where indicated;

• physiotherapy;

• sleep optimisation;

• psychological pain-management strategies;

• gradual activity restoration.

Return to Sport and Higher-Level Activity The patient’s goal of returning to surfing, skiing, and snowboarding should be approached progressively.

The medical team does not recommend return to high-impact or high-risk activity until the patient demonstrates:

• adequate neurological recovery;

• stable spinal fusion;

• sufficient lower-limb strength;

• improved foot control;

• acceptable balance;

• absence of progressive neurological symptoms;

• surgeon and rehabilitation-team clearance.

Return to sport should therefore be based on functional milestones rather than time alone.

Overall Clinical Recommendation The medical team’s overall recommendation is to manage this patient through a combined structural, neurological, biological, and rehabilitation strategy.

The main priorities should be:

• Confirm that there is no remaining or recurrent mechanical nerve compression.

• Monitor neurological deficits such as bilateral foot drop carefully.

• Ensure postoperative spinal stability and appropriate healing.

• Use cell therapy only as complementary biological support when clinically appropriate.

• Integrate treatment with structured physiotherapy and gait rehabilitation.

• Monitor objective outcomes over time before drawing conclusions about treatment effectiveness.

In this setting, cell therapy may have a role in supporting the biological environment surrounding affected tissues and complementing rehabilitation, but it should not be expected to replace decompression surgery, correct spinal hardware, reverse established structural degeneration, or guarantee recovery of chronically damaged nerves.

The most appropriate approach is therefore: Structural assessment → neurological review → surgical management when required → supportive regenerative treatment when appropriate → structured rehabilitation → long-term outcome monitoring.

This provides the patient with a realistic, medically responsible treatment pathway while keeping the goals focused on mobility, neurological preservation, pain control, functional recovery, and quality of life.